Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D06FKC
|
||||
Former ID |
DIB006653
|
||||
Drug Name |
Eltoprazine
|
||||
Synonyms |
Piperazine derivative (ADHD), PsychoGenics/ReqMed Company; 5-HT1A/5-HT1B agonist and 5-HT2C antagonist (ADHD), PsychoGenics/ReqMed Company
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Aggressive non-hodgkin's lymphoma [ICD9: 200, 201, 202, 202.8, 208.9; ICD10:C81, C81-C86, C82-C85, C91-C95] | Phase 2 | [523309] | ||
Company |
Amarantus bioscience; psychogenics
|
||||
Structure |
Download2D MOL |
||||
Formula |
C12H16N2O2
|
||||
Canonical SMILES |
C1CN(CCN1)c2cccc3OCCOc23
|
||||
InChI |
1S/C12H16N2O2/c1-2-10(14-6-4-13-5-7-14)12-11(3-1)15-8-9-16-12/h1-3,13H,4-9H2
|
||||
InChIKey |
WVLHGCRWEHCIOT-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 98224-03-4
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | 5-hydroxytryptamine 1A receptor | Target Info | Agonist | [551057] | |
5-hydroxytryptamine 2C receptor | Target Info | Antagonist | [551057] | ||
5-hydroxytryptamine 1B receptor | Target Info | Agonist | [551057], [551730] | ||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
5HT1 type receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
5HT1 type receptor mediated signaling pathway | |||||
WikiPathways | Serotonin HTR1 Group and FOS Pathway | ||||
SIDS Susceptibility Pathways | |||||
Monoamine GPCRs | |||||
GPCRs, Class A Rhodopsin-like | |||||
GPCR ligand binding | |||||
GPCR downstream signalingWP732:Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
Gastrin-CREB signalling pathway via PKC and MAPK | |||||
GPCR downstream signalingWP722:Serotonin HTR1 Group and FOS Pathway | |||||
GPCR downstream signaling | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.